Sangamo Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Biogen Inc.(1.6%),Biogen MA Inc.(1.6%)
Sangamo Therapeutics | 4:持股變動聲明-高管 Willoughby Scott B.
Sangamo Therapeutics | 10-Q:2024財年二季報
Sangamo Therapeutics | 8-K:SANGAMO THERAPEUTICS報告近期業務亮點和2024年第二季度財務業績
Sangamo Therapeutics | 8-K:重大事件
Sangamo Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-BlackRock, Inc.(2.3%)
Sangamo Therapeutics | 4:持股變動聲明-高管 Duraibabu Prathyusha
Sangamo Therapeutics | 4:持股變動聲明-董事 Smith Karen L.
Sangamo Therapeutics | 4:持股變動聲明-董事 Horn Margaret A
Sangamo Therapeutics | 4:持股變動聲明-董事 Markels John
Sangamo Therapeutics | 4:持股變動聲明-董事 Meyers James R
Sangamo Therapeutics | 4:持股變動聲明-董事 PARKER H STEWART
Sangamo Therapeutics | 4:持股變動聲明-董事 Hillan Kenneth J.
Sangamo Therapeutics | 4:持股變動聲明-董事 Carey Robert
Sangamo Therapeutics | 4:持股變動聲明-董事 Beers Courtney
Sangamo Therapeutics | 8-K:重大事件
Sangamo Therapeutics | 4:持股變動聲明-高管 Dubois-Stringfellow Nathalie
Sangamo Therapeutics | 4:持股變動聲明-高管 Willoughby Scott B.
Sangamo Therapeutics | 4:持股變動聲明-高管 Pooler Amy
Sangamo Therapeutics | 4:持股變動聲明-高管 Duraibabu Prathyusha
暫無數據